Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Stock Has Consensus Target Price of $13.86

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) have earned a consensus rating of “Hold” from the nine research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $13.86.

BCYC has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Wednesday, July 8th. Needham & Company LLC cut their price objective on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Finally, Wall Street Zen raised shares of Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th.

Institutional Investors Weigh In On Bicycle Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Armistice Capital LLC grew its position in Bicycle Therapeutics by 8.7% in the fourth quarter. Armistice Capital LLC now owns 3,236,000 shares of the company’s stock valued at $22,911,000 after acquiring an additional 258,000 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Bicycle Therapeutics by 72.8% during the first quarter. Renaissance Technologies LLC now owns 979,300 shares of the company’s stock worth $4,544,000 after purchasing an additional 412,700 shares in the last quarter. Flax Pond Capital LLC purchased a new position in shares of Bicycle Therapeutics in the fourth quarter valued at $1,229,000. Principal Financial Group Inc. boosted its stake in shares of Bicycle Therapeutics by 2.3% in the first quarter. Principal Financial Group Inc. now owns 1,174,625 shares of the company’s stock valued at $5,450,000 after purchasing an additional 26,353 shares during the period. Finally, R Squared Ltd acquired a new stake in Bicycle Therapeutics during the 1st quarter valued at $98,000. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Stock Performance

Shares of NASDAQ BCYC opened at $3.56 on Friday. Bicycle Therapeutics has a one year low of $3.55 and a one year high of $9.16. The firm has a market capitalization of $249.16 million, a P/E ratio of -1.30 and a beta of 1.68. The company’s fifty day moving average is $3.97 and its two-hundred day moving average is $4.33.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.14). Bicycle Therapeutics had a negative net margin of 311.11% and a negative return on equity of 33.22%. The company had revenue of $0.63 million for the quarter, compared to analyst estimates of $4.22 million. On average, sell-side analysts forecast that Bicycle Therapeutics will post -2.26 earnings per share for the current fiscal year.

About Bicycle Therapeutics

Bicycle Therapeutics plc (NASDAQ:BCYC) is a clinical-stage biopharmaceutical company developing medicines based on its proprietary Bicycle technology. The platform uses small, constrained peptides designed to bind selectively to biological targets, with the goal of combining the tissue penetration and manufacturing advantages of small molecules with the target specificity often associated with larger biologic medicines.

The company’s research and development activities are focused primarily on oncology.